Disclosure notice in BioGaia


Sebastian Jahreskog, BioGaia's second largest shareholder, has announced that he
has sold his shares in BioGaia to an endowment insurance. With this, he flagged
a sale. The transaction only means a modified form of ownership and Sebastian
Jahreskog intends to retain his holdings of BioGaia.

Latest press releases from BioGaia
2016-10-25 BioGaia AB Interim Management statement 1 January – 30 September 2016
2016-10-14 BioGaia’s probiotics to be launched in Kenya, Nigeria and Ghana
2016-08-17 BioGaia AB, Interim Report 1 January – 30 June 2016
For additional information please contact
Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri which has probiotic, health-
enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the Nasdaq OMX Nordic Exchange Stockholm.
www.biogaia.com.

BioGaia AB Box 3242. SE-103 64 STOCKHOLM Street address: Kungsbroplan 3A,
Stockholm Telephone: +46 8 555 293 00, Corp. identity no. 556380
-8723. www.biogaia.com.

Attachments

10313794.pdf